Quality of Life in Japanese Pediatric Alopecia Areata

Not Applicable

Recruiting

• Conditions: Pediatric alopecia areata; Pediatric, alopecia areata, Pfizer; D000506

• Registration Number: JPRN-jRCT1030230428
• Lead Sponsor: Yamanaka Kenichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-03
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Diagnosed with AA and age 5 to 15 years

Exclusion Criteria

Have primarily diffuse type of AA (characterized by widespread reduction of hair
density rather than clearly defined patches of hair loss).
2. Are currently experiencing other forms of alopecia including, but not limited to,
telogen effluvium, chemotherapy-induced hair loss, or any other concomitant
conditions (for example, Down syndrome, tinea capitis, psoriasis, lupus
erythematosus, or secondary syphilis) that would interfere with the evaluation of the
effect of study medication on AA.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Children's Dermatology Life Quality Index (CDLQI)

Secondary Outcome Measures

Name	Time	Method
Subpopulation analysis of CDLQI and Pediatric Quality of Life Inventory (PedsQL) scores per hair loss range.